Compounds in phase I or phase II clinical trials targeting classical PKC isoforms were not successful [31], but recent studies implicate that mainly atypical and novel PKC enzymes regulate oncogenic signaling pathways in pancreatic cancer. This evidence concerns the gene PRRT2 and pancreatic neoplasm.